Skip to main content
Premium Trial:

Request an Annual Quote

Forma, Novartis in Protein Interaction Screening Deal

NEW YORK (GenomeWeb News) – Forma Therapeutics today said that it will collaborate with Novartis on screening drug candidates for oncology applications.

The Cambridge, Mass.-based firm said that it would utilize its cell-based screening platform to identify inhibitors for undisclosed protein-protein interaction targets. Financial and other terms of the alliance were not disclosed.

Steven Tregay, CEO of Forma, said that the alliance with Novartis "provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery."

Filed under

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.